American Society of Hematology

As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.

Content to be used in accordance with local CPO guidelines

cart

CAR-T

List of Presentations

CAR-T CML Early Pipeline ITP/SAA LCH MDS/AML/AdvSM MPN/GvHD PNH SCD

A Propensity Score Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-life: A LYSA Study From the DESCAR-T Registry

Bachy E

  • Presentation # 92 – Oral
    December 11, 2021 | 09:45 AM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing After Anti-CD19 CAR T-Cells and Enrolled in the DESCAR-T French National Registry

Di Blasi R

  • Presentation # 885 – Oral
    December 13, 2021 | 06:45 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Real-World Outcomes for Pediatric and Young Adult Patients With Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated With Tisagenlecleucel: Update From the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

John S

  • Presentation # 428 – Oral
    December 12, 2021 | 09:45 AM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Real-World Efficacy and Safety Outcomes for Patients With Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin’s Lymphoma (aBNHL) Treated With Commercial Tisagenlecleucel: Update From the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Landsburg D

  • Presentation # 429 – Oral
    December 12, 2021 | 10:00 AM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Efficacy of Tisagenlecleucel in Adult Patients (Pts) With High-Risk Relapsed/Refractory Follicular Lymphoma (R/R FL): Subgroup Analysis of the Phase II ELARA Study

Thieblemont C

  • Presentation # 131 – Oral
    December 11, 2021 | 01:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Treatment Regimens and Clinical Outcomes Among Follicular Lymphoma Patients Treated With Third-line Therapy in the United States: A Real-world EHR Study

Bollu V

  • Presentation # 1360 – Poster
    December 11, 2021 | 05:30 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Assessment of Healthcare Resource Utilization and Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study

Fowler N

  • Presentation # 3533 – Poster
    December 13, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Comparison of Clinical Outcomes Among Patients With Relapsed/Refractory Follicular Lymphoma Treated With Tisagenlecleucel in the ELARA Trial Versus a Real-World External Control Arm of Patients Treated With Standard of Care

Hao Y

  • Presentation # 2419 – Poster
    December 12, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Optimizing Commercial Manufacturing of Tisagenlecleucel for Patients in the US: A 4-Year Experiential Journey

Rodrigues M

  • Presentation # 1768 – Poster
    December 11, 2021 | 05:30 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma (ReCORD-FL)

Salles G

  • Presentation # 1349 – Poster
    December 11, 2021 | 05:30 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients With Relapsed or Refractory Follicular Lymphoma

Salles G

  • Presentation # 3528 – Poster
    December 13, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Pediatric Acute Lymphoblastic Leukemia: Database Analysis of Patients and Treatments in a National Public Healthcare System

Seber A

  • Presentation # 4105 – Poster
    December 13, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Tisagenlecleucel Leukapheresis and Manufacturing Outcomes in Patients Less Than 3 Years of Age With Relapsed/Refractory Acute Lymphoblastic Leukemia

Willert J

  • Presentation # 3882 – Poster
    December 13, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Utilization of External Control Arm to Contextualize Clinical Efficacy of Tisagenlecleucel Treated Among Patients With Relapsed/Refractory Follicular Lymphoma From the Single-Arm ELARA Trial

Hao Y

  • Presentation # 4506 – Publication Only
    Friday, November 5, 2021

  • Abstract
This presentation will be available once the congress embargo lifts

Tisagenlecleucel vs Standard of Care as Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III BELINDA Study

Bishop MR

  • Presentation # LBA-6 – Oral
    December 14, 2021 | 10:15 AM EST

  • Abstract
This presentation will be available once the congress embargo lifts

A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge™ Platform, for the Treatment of Patients (Pts) With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Flinn I

  • Presentation # 740 – Oral
    December 13, 2021 | 03:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Preservation of T-Cell Stemness With a Novel Expansionless CAR-T Manufacturing Process, Which Reduces Manufacturing Time to Less Than Two Days, Drives Enhanced CAR-T Cell Efficacy

Engels B

  • Presentation # 2848 – Poster
    December 12, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Identification and Development of PHE885: A Novel and Highly Potent Fully Human Anti-BCMA CAR-T Manufactured With a Novel T-ChargeTM Platform for the Treatment of Multiple Myeloma

Bu D

  • Presentation # 2770 – Poster
    December 12, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-ChargeTM Platform

Sperling A

  • Presentation # 3864 – Poster
    December 13, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts
View list of select presentations for this compound